Graham Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Graham Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.59M	Buy	42,662 +11,348	+36%	+$662K	0.06%	226
2025 Q4	$1.69M	Buy	31,314 +16,611	+113%	+$799K	0.04%	267
2025 Q3	$663K	Sell	14,703 -46,282	-76%	-$2.16M	0.01%	516
2025 Q2	$2.82M	Buy	60,985 +51,671	+555%	+$2.54M	0.04%	264
2025 Q1	$568K	Buy	+9,314	New	+$543K	0.01%	757
2024 Q4	–	Sell	-130,485	Closed	-$6.75M	–	1241
2024 Q3	$6.75M	Buy	130,485 +56,170	+76%	+$2.63M	0.12%	96
2024 Q2	$3.09M	Buy	74,315 +56,676	+321%	+$2.54M	0.07%	162
2024 Q1	$957K	Sell	17,639 -24,180	-58%	-$1.23M	0.02%	439
2023 Q4	$2.15M	Buy	+41,819	New	+$2.2M	0.05%	201
2023 Q3	–	Sell	-47,580	Closed	-$3.04M	–	1028
2023 Q2	$3.04M	Buy	+47,580	New	+$3.19M	0.09%	157
2023 Q1	–	Sell	-21,072	Closed	-$1.52M	–	1066
2022 Q4	$1.52M	Buy	+21,072	New	+$1.59M	0.05%	383
2022 Q2	–	Sell	-3,791	Closed	-$276K	–	1017
2022 Q1	$276K	Buy	+3,791	New	+$255K	0.01%	753
2017 Q1	–	Sell	-16,800	Closed	-$982K	–	98
2016 Q4	$982K	Buy	+16,800	New	+$918K	0.04%	77

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Graham Capital Management's BMY Position: Q1 2026 in Review

Graham Capital Management increased its Bristol-Myers Squibb (BMY) stake by 36% in Q1 2026, buying an estimated $662K and bringing the position to 42,662 shares worth $2.59M. The position accounts for 0.06% of the portfolio, ranked #226.

Graham Capital Management first reported a position in BMY in Q4 2016 and has held it in 13 quarters since. The position peaked at $6.75M in Q3 2024. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Graham Capital Management held 42,662 shares of Bristol-Myers Squibb worth $2.59M as of Q1 2026.
Graham Capital Management bought 11,348 Bristol-Myers Squibb shares in Q1 2026, an estimated $662K.
Bristol-Myers Squibb made up 0.06% of Graham Capital Management's portfolio in Q1 2026, its #226 holding.
Graham Capital Management first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 13 quarters since.
Graham Capital Management's Bristol-Myers Squibb position peaked at $6.75M in Q3 2024.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.